Waystar Explores Sale Options Amid Rich Valuation and Leverage

What happened

Waystar Holding Corp., a provider of healthcare payment software, is exploring strategic alternatives including a potential sale that could take the company private, according to a Reuters report citing seven sources familiar with the matter, just two years after its June 2024 IPO. The company has demonstrated robust business fundamentals, with over 99% recurring or predictable revenue, net revenue retention of 110.1%, revenue growth from $704.9 million in 2022 to $943.5 million in 2024, and a recent inflection to profitability with $92.1 million in net income for the first nine months of 2025. Despite these strengths, the stock trades at premium multiples—approximately 58 times trailing earnings and 13.5 times EV/EBITDA—while carrying significant leverage at 3.5 times net debt to EBITDA and interest coverage of only 3.3 times, which led the master report to assign a WAIT rating due to limited margin of safety. The exploration of a sale could be motivated by a desire to unlock value or address the capital structure away from public market scrutiny, particularly given the need to integrate acquisitions like Iodine and reduce debt over time. The news introduces a potential catalyst that could change the risk-reward profile, but until concrete offers emerge, the outcome remains uncertain.

Implication

The strategic review could lead to a take-private transaction that eliminates the public market discount to intrinsic value identified in the master report's DCF analysis, offering shareholders an exit at potentially higher prices. However, if no deal materializes, the stock may revert toward fundamentals, which are solid but already priced for high growth, leaving limited upside. Current holders might benefit from an acquisition premium, but new investors should weigh the rich valuation and high leverage against the binary outcome of a sale process. A successful transaction would likely require a buyer willing to absorb the company's debt and regulatory risks, and the timeline and terms are highly uncertain. Overall, the news adds a speculative event that could resolve the valuation tension either positively or negatively, warranting close monitoring.

Thesis delta

The news of a potential sale introduces a near-term catalyst that could lead to a premium take-private offer, potentially providing shareholders with an exit above current trading levels. This adds a speculative upside scenario beyond the fundamental WAIT stance, but the core valuation and leverage concerns from the master report remain unchanged. Therefore, the investment thesis shifts from a pure fundamental wait to a wait with acknowledgment of a potential event-driven catalyst, contingent on deal specifics.